Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MorphoSys (MOR)

MorphoSys AG
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MOR
DateTimeSourceHeadlineSymbolCompany
12/07/202420:59Business WireMorphoSys Announces Voluntary Delisting from the Nasdaq Global MarketNASDAQ:MORMorphoSys AG
08/07/202412:03PR Newswire (US)Kuehn Law Encourages DM, SHCR, MOR, and ALE Investors to Contact Law FirmNASDAQ:MORMorphoSys AG
20/06/202406:47Business WireMorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority ShareholdersNASDAQ:MORMorphoSys AG
10/06/202415:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
06/06/202420:36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
05/06/202414:22Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
04/06/202420:06Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:MORMorphoSys AG
04/06/202414:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
31/05/202414:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
29/05/202414:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
28/05/202414:16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
24/05/202414:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
23/05/202418:19Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:MORMorphoSys AG
23/05/202414:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
23/05/202413:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
21/05/202414:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
17/05/202414:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
17/05/202414:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
16/05/202420:43Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:MORMorphoSys AG
16/05/202414:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
15/05/202414:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
13/05/202414:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
29/04/202420:01Business WireMorphoSys AG Reports First Quarter 2024 Financial ResultsNASDAQ:MORMorphoSys AG
11/04/202412:39Business WireMorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisNASDAQ:MORMorphoSys AG
13/03/202420:02Business WireMorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:MORMorphoSys AG
06/02/202411:14IH Market NewsBoeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and MoreNASDAQ:MORMorphoSys AG
11/12/202300:31Business WireMorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 StudyNASDAQ:MORMorphoSys AG
20/11/202322:19Dow Jones NewsMorphoSys Trial for Blood-Cancer Treatment Reaches Primary EndpointNASDAQ:MORMorphoSys AG
20/11/202321:30Business WireMorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom ReductionNASDAQ:MORMorphoSys AG
15/11/202321:01Business WireMorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial ResultsNASDAQ:MORMorphoSys AG
 Showing the most relevant articles for your search:NASDAQ:MOR